Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Dow
Baxter
Julphar
Queensland Health
Citi
Mallinckrodt
UBS
Colorcon
Daiichi Sankyo

Generated: August 16, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 017530

« Back to Dashboard
NDA 017530 describes TIGAN, which is a drug marketed by Par Sterile Products and King Pharms Llc and is included in two NDAs. It is available from five suppliers. Additional details are available on the TIGAN profile page.

The generic ingredient in TIGAN is trimethobenzamide hydrochloride. There are six drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the trimethobenzamide hydrochloride profile page.

Summary for NDA: 017530

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antiemetics
Formulation / Manufacturing:see details

Pharmacology for NDA: 017530

Physiological EffectEmesis Suppression

Suppliers and Packaging for NDA: 017530

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TIGAN
trimethobenzamide hydrochloride
INJECTABLE;INJECTION 017530 NDA Rebel Distributors Corp 21695-853 21695-853-20 1 VIAL, MULTI-DOSE in 1 CARTON (21695-853-20) > 20 mL in 1 VIAL, MULTI-DOSE
TIGAN
trimethobenzamide hydrochloride
INJECTABLE;INJECTION 017530 NDA Par Pharmaceutical, Inc. 42023-118 42023-118-01 1 VIAL, MULTI-DOSE in 1 CARTON (42023-118-01) > 20 mL in 1 VIAL, MULTI-DOSE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength100MG/ML
Approval Date:Approved Prior to Jan 1, 1982TE:APRLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Teva
Accenture
Mallinckrodt
Fuji
Chinese Patent Office
Boehringer Ingelheim
Queensland Health
QuintilesIMS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot